-The Times of India MUMBAI: In a move that has surprised and shaken the industry, prices of widely-used expensive anti-diabetic and cardiac medicines will reduce by as much as 35% over the next few weeks, with the drug pricing regulator, National Pharmaceutical Pricing Authority (NPPA), deciding to bring them under price control. In a rare invocation of a lesser-used provision in the Drug Price Control Order (DPCO), NPPA has fixed the prices...

-Press Information Bureau (Ministry of Health and Family Welfare)     Dr Harsh Vardhan, Union Minister for Health and Family Welfare, has asked for thorough streamlining of systems in the distribution of free generic drugs to government health institutions at all levels throughout the country. The Free Drug Programme's formal launch would be preceded by working out all logistical details with respect to procurement and distribution in consultation with the state governments. The...

-The Times of India   NEW DELHI: The World Health Organisation's (WHO) work of setting up norms and standards for production of medicines seems to be flawed by a fundamental conflict of interest. At the heart of its standard setting work is an entity the International Conference on Harmonization (ICH) in which majority of the WHO member countries have no voting rights and which is dominated by pharmaceutical industry groups. This glaring...

-Frontline   A Delhi High Court verdict says the State government is bound to ensure that poor and vulnerable sections of society have access to treatment for rare and chronic diseases. SEVEN-YEAR-OLD Mohammed Ahmed Khan looked on helplessly as his father, Sirajuddin, narrated the sordid tale of the loss of four of his children to Gaucher's disease, a rare genetic disease that requires lifelong, exorbitantly expensive enzyme replacement therapy. Sirajuddin, a rickshaw...

-The Hindu A strong whistle-blower protection law in India would expose financial corruption in a way that reinforces ethical business practices In 2013, generic pharmaceutical company Ranbaxy pleaded guilty to seven criminal felonies for drug manufacturing fraud and agreed to cough up an unprecedented $500 million in fines. The case against Ranbaxy was significant not only for being a successful prosecution of a powerful India corporation. It also marked the triumph of Dinesh...